Saturday, October 31, 2026

Several Astronauts Who Already Orbited the Earth to Meet in Budapest

ViaNews Editorial Team

October 27, 2021

ASE congress 2019

From 1st to 5th November, 2021, Budapest will host the 33rd Congress of the Association of Space Explorers (ASE). Several astronauts, who have already orbited Earth will attend congress by invitation of Bertalan Farkas, the first Hungarian cosmonaut.

ASE was founded in 1985 by a small group of US, Russian, and international fliers. It's an international nonprofit organization of over 400 flown astronauts and cosmonauts from 38 nations.

ASE congress in 2019.

Hosting the conference is another step by the Hungarian government to promote its national space research together with Hungarian universities, research institutes, and businesses.

Several space instruments developed in Hungary have recently been deployed, such as the pocket-class satellites of the Budapest University of Technology and the Pille and Tritel radiation measuring instruments that have been used on the International Space Station.

Péter Szijjártó, Minister of Foreign Affairs and Trade had announced this last summer a new milestone in Hungarian space research, following the government's Space Strategy, of another research astronaut by 2025.

This annual congress of astronauts, now preparing to come to Budapest, is organized by the US-based Association of Space Explorers (ASE), which currently has a membership of around 400 astronauts from 38 countries.

Around half a hundred astronauts are expected to attend the Congress, taking part in professional and educational programs throughout the week.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com